skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Dr Reddys Joins Remdesivir Licensees

Dr Reddy’s has become the latest licensee of Gilead’s remdesivir after striking a non-exclusive deal with the originator to make and market a generic version of the potential COVID-19 treatment.

The agreement “will grant Dr Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, remdesivir, a potential treatment for COVID-19, in 127 countries including India,” the firm announced.

A month ago, Gilead announced that it had agreed licenses with five firms – Cipla, Ferozsons, Hetero, Jubilant and Mylan – to manufacture remdesivir for distribution in 127 countries across the globe. (Also see "Gilead Licenses Remdesivir To Five Firms" - Generics Bulletin, 13 May, 2020.)

Under the terms of the agreements, Gilead said the licensees “have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly” and may also “set their own prices for the generic product they produce.”

The licenses will be royalty-free until the World Health Organization declares the end of the COVID-19 pandemic international public health emergency “or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, whichever is earlier,” Gilead indicated.

Noting that it would receive technology transfer from Gilead to manufacture its generics, Dr Reddy’s said it “would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries.”

The investigational antiviral therapy developed by Gilead has already received an Emergency Use Authorization from the US Food and Drug Administration to treat hospitalized COVID-19 patients.  (Also see "After Remdesivir's Emergency Use Authorization, US Gov't Must Now Decide How To Distribute Limited Supply" - Scrip, 1 May, 2020.) It is also recommended for compassionate use in Europe and recently received regulatory approval in Japan.

Bangladesh’s Beximco recently became the first firm worldwide to launch a generic version of remdesivir, circumventing Gilead’s intellectual property via the World Trade Organization’s transitional period for least developed countries, which means that firms in Bangladesh can manufacture the product for local consumption without infringing the patent. (Also see "Beximco Launches First Remdesivir Generic" - Generics Bulletin, 21 May, 2020.)

Shortly after, The Searle Company announced a licensing deal with Beximco allowing it to market the firm’s generic remdesivir in Pakistan. (Also see "Searle Licenses Beximco’s Remdesivir For Pakistan" - Generics Bulletin, 29 May, 2020.)

 

おすすめのニュース&レポート

;

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。